China Shineway Pharmaceutical Group Limited (FRA:C1S)
0.8500
+0.0300 (3.66%)
At close: May 13, 2025, 10:00 PM CET
FRA:C1S Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 6,140 | 5,889 | 5,026 | 4,206 | 3,943 | Upgrade
|
Short-Term Investments | 4.48 | 4.02 | 3.69 | 4.32 | 5.32 | Upgrade
|
Trading Asset Securities | 350.02 | 20 | 20.23 | - | - | Upgrade
|
Cash & Short-Term Investments | 6,495 | 5,913 | 5,050 | 4,210 | 3,948 | Upgrade
|
Cash Growth | 9.84% | 17.08% | 19.96% | 6.63% | -0.52% | Upgrade
|
Accounts Receivable | 1,202 | 1,260 | 975.06 | 825.18 | 760.66 | Upgrade
|
Other Receivables | 66.81 | 63.92 | 67.48 | 40.87 | 23.07 | Upgrade
|
Receivables | 1,269 | 1,324 | 1,043 | 866.05 | 783.73 | Upgrade
|
Inventory | 813.19 | 897.71 | 657.66 | 587.96 | 443 | Upgrade
|
Other Current Assets | 22 | 19.94 | 32.01 | 35.06 | 343.99 | Upgrade
|
Total Current Assets | 8,599 | 8,155 | 6,782 | 5,699 | 5,519 | Upgrade
|
Property, Plant & Equipment | 1,219 | 1,205 | 1,217 | 1,252 | 1,395 | Upgrade
|
Goodwill | 165.96 | 165.96 | 165.96 | 165.96 | 102.5 | Upgrade
|
Other Intangible Assets | 23.32 | 32.79 | 47.35 | 66.43 | 36.96 | Upgrade
|
Long-Term Deferred Tax Assets | 34.33 | 15.23 | 19.22 | 20.47 | 23.1 | Upgrade
|
Other Long-Term Assets | - | - | - | - | 137.14 | Upgrade
|
Total Assets | 10,042 | 9,574 | 8,232 | 7,204 | 7,214 | Upgrade
|
Accounts Payable | 402.96 | 484.79 | 308.75 | 228.62 | 164.38 | Upgrade
|
Accrued Expenses | 1,199 | 1,121 | 856.76 | 483.21 | 319.13 | Upgrade
|
Short-Term Debt | 330 | 300 | - | - | 369.32 | Upgrade
|
Current Portion of Leases | 8.27 | 0.97 | 6.53 | 7.59 | 7.79 | Upgrade
|
Current Income Taxes Payable | 84.27 | 105.91 | 107.79 | 65.1 | 58.37 | Upgrade
|
Current Unearned Revenue | 101.75 | 127.4 | 165.22 | 117.05 | 78.42 | Upgrade
|
Other Current Liabilities | 323.67 | 294.13 | 220.54 | 196.81 | 197.28 | Upgrade
|
Total Current Liabilities | 2,450 | 2,434 | 1,666 | 1,098 | 1,195 | Upgrade
|
Long-Term Leases | 8.26 | 0.36 | 0.91 | 7.32 | 15.03 | Upgrade
|
Long-Term Unearned Revenue | 81.85 | 88.89 | 163.99 | 171.59 | 204.31 | Upgrade
|
Long-Term Deferred Tax Liabilities | 34.52 | 16.26 | 18.84 | 25.19 | 5.3 | Upgrade
|
Total Liabilities | 2,575 | 2,539 | 1,849 | 1,302 | 1,419 | Upgrade
|
Common Stock | 87.66 | 87.66 | 87.66 | 87.66 | 87.66 | Upgrade
|
Additional Paid-In Capital | 422.14 | 422.14 | 422.14 | 422.14 | 422.14 | Upgrade
|
Retained Earnings | 7,452 | 7,020 | 6,368 | 5,879 | 5,778 | Upgrade
|
Comprehensive Income & Other | -494.89 | -494.89 | -494.89 | -487.32 | -493.42 | Upgrade
|
Total Common Equity | 7,467 | 7,035 | 6,383 | 5,901 | 5,794 | Upgrade
|
Shareholders' Equity | 7,467 | 7,035 | 6,383 | 5,901 | 5,794 | Upgrade
|
Total Liabilities & Equity | 10,042 | 9,574 | 8,232 | 7,204 | 7,214 | Upgrade
|
Total Debt | 346.53 | 301.33 | 7.44 | 14.91 | 392.14 | Upgrade
|
Net Cash (Debt) | 6,148 | 5,611 | 5,043 | 4,195 | 3,556 | Upgrade
|
Net Cash Growth | 9.56% | 11.28% | 20.21% | 17.97% | -0.23% | Upgrade
|
Net Cash Per Share | 8.14 | 7.43 | 6.68 | 5.56 | 4.70 | Upgrade
|
Filing Date Shares Outstanding | 755.4 | 755.4 | 755.4 | 755.4 | 754.6 | Upgrade
|
Total Common Shares Outstanding | 755.4 | 755.4 | 755.4 | 755.4 | 754.6 | Upgrade
|
Working Capital | 6,149 | 5,721 | 5,117 | 4,601 | 4,324 | Upgrade
|
Book Value Per Share | 9.88 | 9.31 | 8.45 | 7.81 | 7.68 | Upgrade
|
Tangible Book Value | 7,278 | 6,836 | 6,169 | 5,669 | 5,655 | Upgrade
|
Tangible Book Value Per Share | 9.63 | 9.05 | 8.17 | 7.50 | 7.49 | Upgrade
|
Machinery | 1,494 | 1,489 | 1,438 | 1,392 | 1,388 | Upgrade
|
Construction In Progress | 195.51 | 117.68 | 193.06 | 130.17 | 115.5 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.